GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Whitehawk Therapeutics Inc (NAS:WHWK) » Definitions » Price-to-Owner-Earnings

WHWK (Whitehawk Therapeutics) Price-to-Owner-Earnings : (As of May. 11, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Whitehawk Therapeutics Price-to-Owner-Earnings?

As of today (2025-05-11), Whitehawk Therapeutics's share price is $1.70. Whitehawk Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Whitehawk Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


WHWK's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 28.43
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-11), Whitehawk Therapeutics's share price is $1.70. Whitehawk Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-2.35. Therefore, Whitehawk Therapeutics's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-11), Whitehawk Therapeutics's share price is $1.70. Whitehawk Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.25. Therefore, Whitehawk Therapeutics's PE Ratio without NRI for today is At Loss.


Whitehawk Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Whitehawk Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Whitehawk Therapeutics Price-to-Owner-Earnings Chart

Whitehawk Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
- - - - -

Whitehawk Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Whitehawk Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Whitehawk Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Whitehawk Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Whitehawk Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Whitehawk Therapeutics's Price-to-Owner-Earnings falls into.


;
;

Whitehawk Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Whitehawk Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.70/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Whitehawk Therapeutics  (NAS:WHWK) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Whitehawk Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Whitehawk Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Whitehawk Therapeutics Business Description

Traded in Other Exchanges
Address
2 Headquarters Plaza East Building, 11th Floor, Morristown, New Jersey, NJ, USA, 07960
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Executives
David James Lennon director, officer: Chief Executive Officer C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD, SUITE A250, PACIFIC PALISADES CA 90272
Scott M. Giacobello officer: Chief Financial Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Neil Desai director, officer: See Remarks C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Mohammad Hirmand director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Lorettta M Itri officer: Chief Medical Officer
Brendan Delaney officer: Chief Operating Officer 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Karin M. Hehenberger director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON CO 01803
Richard E Maroun director C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Lance E Thibault officer: Chief Financial Officer
Behzad Aghazadeh director, other: See Remarks C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Venbio Select Advisor Llc director, other: See Remarks 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Anupam Dalal director 88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Avoro Ventures Llc director, other: See Remarks 110 GREEN STREET, SUITE 800, NEW YORK NY 10012